173 related articles for article (PubMed ID: 34166587)
1. Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER-MPH in Children With ADHD.
Childress AC; Cutler AJ; Po MD; DeSousa NJ; Warrington LE; Sallee FR; Incledon B
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34166587
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
[No Abstract] [Full Text] [Related]
4. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
Childress AC; Uchida CL; Po MD; DeSousa NJ; Incledon B
Clin Ther; 2020 Dec; 42(12):2332-2340. PubMed ID: 33168234
[TBL] [Abstract][Full Text] [Related]
5. Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate.
Wilens TE; Faraone SV; Hammerness PG; Pliszka SR; Uchida CL; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Atten Disord; 2022 Mar; 26(5):696-705. PubMed ID: 34085581
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
[No Abstract] [Full Text] [Related]
7. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
8. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
López FA; Faraone SV; Newcorn JH; Doll HA; Rhoten S; Lewis HB; Khan TF; DeSousa NJ; Sallee FR; Incledon B
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):179-186. PubMed ID: 33797983
[No Abstract] [Full Text] [Related]
9. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
10. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
[No Abstract] [Full Text] [Related]
11. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
13. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
14. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V
Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
16. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial.
Weiss M; Childress A; Mattingly G; Nordbrock E; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):521-529. PubMed ID: 30036076
[TBL] [Abstract][Full Text] [Related]
18. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
Childress AC; Marraffino A; Cutler AJ; Oh C; Brams MN
J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):51-58. PubMed ID: 36809150
[No Abstract] [Full Text] [Related]
20. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
